Jay Mehta
I read with great interest the Perspectives article by Dr Tim Niehues (Optimizing treatment in paediatric rheumatology -lessons from oncology. Nat. Rev. Rheumatol. 11, 493-499; 2015) 1 published in April 2015. Dr Niehues is correct in his assertion that some paediatric rheumatic diseases are as aggressive and fatal as childhood malignancies. I would point to juvenile systemic lupus erythematosus (SLE) and macrophage activation syndrome as two common rheumatic diseases which are potentially fatal if untreated. I agree with Dr Niehues that children with a rheumatic disease would benefit greatly from enrolment in treatment-optimizing study protocols such as those used in paediatric oncology. Indeed, the reduction in mortality from paediatric cancer is one of the greatest achievements in child health of the past few years.
The Childhood Arthritis and Rheumatology Research Alliance (CARRA), of which Dr Niehues makes brief mention, was formed to enrol every child with a rheumatic disease in a research study as one of its intents. A major focus of CARRA resources has been the development of consensus treatment plans (CTPs) for the major rheumatic diseases, including polyarticular juvenile idio pathic arthritis (JIA) 2 , systemic JIA 3 , lupus nephritis 4 , juven ile dermatomyositis 5 and juvenile localized sclero derma 6 . These CTPs have been developed through a rigorous process that includes surveys, expert opinion and face-to-face meetings of paediatric rheumatologists to achieve standardization and consensus and, consequently, increase the power of observational studies. Each CTP includes information on timing, dosage and data collection parameters and schedules. Many of the CTPs include specimen collection for future pharma cogenomic analyses and other translational studies. These CTPs will be implemented through CARRA Registry sites, enabling observational, comparative and effectiveness studies. Through an iterative process, the best treatments for these diseases will be identified. Results from pilot studies 7, 8 have suggested that CARRA sites are highly effective at enrolling patients into CTPs, suggesting that we will be able to approach Dr Niehues's goal of standardization in paediatric rheumatology research. The process for creating CTPs has begun for paediatric antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and chronic noninfectious osteomyelitis, two rheumatic diseases with potentially devastating consequences.
A major difference between CARRA's approach and that used in paediatric oncology is that the paediatric rheumatology CTPs are observational rather than randomized clinical trials. Although enrolment of each child with a rheumatic disease into a clinical trial is a goal that the paediatric rheumatologist com munity should be striving towards, as Dr Niehues states, this process took decades and dedicated NIH funding for the paediatric oncology group. Through CARRA, and other organizations such as the Paediatric Rheumatology International Trials Organization (PRINTO), we are well on our way to achieving that goal.
